J&J shares have good upside-Barron’s

NEW YORK, May 9 (BestGrowthStock) – Shares of Johnson & Johnson
(JNJ.N: ) may come under pressure in the short term following the
recent recall of its pediatric Tylenol and other products, but
the company’s long-term prospects remain “sound,” Barron’s said
in its May 10 edition.

Johnson & Johnson, which has had four recalls in the past
year of over-the-counter medicines, most recently on April 30,
has a diversified set of businesses, a strong balance sheet and
a promising product pipeline, the financial newspaper said.

Citing Scott Glasser, co-portfolio manager of the
large-cap-blend Legg Mason ClearBridge Appreciation Fund
(SHAPX.O: ) Barron’s wrote that the products affected by the most
recent recall make up less than 1 percent of Johnson &
Johnson’s expected 2010 revenue.

Johnson & Johnson were down 9 cents, or 0.1 percent, to
close at $63.31 on Friday on the New York Stock Exchange.

Stock Basics

(Reporting by Phil Wahba)

J&J shares have good upside-Barron’s